ImmunoGen Inc (IMGN)

[XenaLives]

ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting
November 6, 2019 at 9:01 AM EST

Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN

Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 6, 2019-- ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts highlighting the Company’s investigational ADC therapy, IMGN632, have been accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting to be held December 7-10 in Orlando, FL.

IMGN632 is a CD123-targeting ADC in Phase I testing for hematological malignancies, including acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and acute lymphocytic leukemia (ALL). IMGN632 uses one of ImmunoGen's novel indolino-benzodiazepine (IGN) payloads, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against AML blasts, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads.

Updated safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients with relapsed/refractory AML and BPDCN will be reported in an oral presentation. Preclinical data related to IMGN632 in combination with Vidaza® (azacitidine) and Venclexta® (venetoclax) and two “trial in progress” posters will also be presented in poster sessions.

“Building on initial data shared at ASH last year, we continue to be encouraged by the anti-leukemia activity and tolerability of IMGN632 in AML and BPCDN,” said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen. “These data support the continued development of IMGN632 as a monotherapy for BPDCN and MRD+ AML, and in combinations for AML. Despite recent advances, including the first drug approved for BPDCN and approvals of targeted therapies for molecularly-defined subsets of AML, the need remains for well-tolerated, effective, and convenient therapies in these diseases.”

http://investor.immunogen.com/node/19011/pdf